Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status

Study Overview
=================
Brief Summary
-----------------
BAY2327949 is currently under clinical development for chronic kidney disease. The goal of this study is to learn more about how the body absorbs, distributes and excretes the study drug when taken once per mouth as 30mg tablet. An additional important goal of this study is to gain more information on how well the study drug is tolerated and its effect on the human body functions. The study will enroll healthy participants or patients with mild, moderate or severe reduced kidney functions matched for age, weight and gender. The results of this study will help researchers to select the best dosing of the study drug for future studies in patients.

Official Title
-----------------
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Oral Dose of BAY2327949 Given as Immediate Release Tablet in Male and Female Participants in a Multi-center, Non-randomized, Non-controlled, Non-blinded Study With Group Stratification in Participants With Renal Impairment and Healthy Participants Matched for Age, Gender, and Weight

Conditions
-----------------
Pharmacokinetics

Intervention / Treatment
-----------------
* Drug: BAY2327949


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant must be ≥18 years of age The study enrolls healthy participants and participants at different stages of renal impairment (mild to severe renal impairment). Race: White BMI (body mass index): above or equal 18.5 and below or equal 35 kg/m*2 at the first screening visit. Male or female. Participants with renal impairment must have an eGFR (estimated glomerular filtration rate) <90 mL/min/1.73 m*2 determined from serum creatinine 21-3 days prior to dosing using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation (eGFR has to be repeated if screening period >10 days before dosing). Stable renal function, e.g. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit confirmed by nephrologist or general practitioner the patient is under care. Exclusion Criteria: Clinically relevant findings in the physical examination affecting the objectives of the study. Systemic use of the following co-medications from 2 weeks before administration until end of follow-up: Moderate and strong inhibitors of CYP3A; Moderate and strong CYP3A inducers; Moderate and strong inhibitors of P-gp transport; UDP-glucuronosyltransferase (UGT) inhibitors probenecid and valproic acid. Regular daily consumption of more than 10 cigarettes. Acute renal failure. Active nephritis. Impairment of any other major organ system other than the kidney. Change in chronic medications for renal disease (or its consequences) less than 4 weeks prior to dosing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healthy participants<br> | Drug: BAY2327949<br>* A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)<br>|
| Experimental: Participants with mild renal impairment<br> | Drug: BAY2327949<br>* A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)<br>|
| Experimental: Participants with moderate renal impairment<br> | Drug: BAY2327949<br>* A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)<br>|
| Experimental: Participants with severe renal impairment<br> | Drug: BAY2327949<br>* A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax of BAY2327949 | Cmax: Maximum observed drug concentration in measured matrix after single dose administration | From pre-dose until follow-up (10-12 days after dosing). | 
| AUC of BAY2327949 | AUC:Area under the concentration vs. time curve from zero to infinity after single (first) dose. AUC(0-tlast) will be used as primary variables if mean AUC(tlast-∞) >20% of AUC | From pre-dose until follow-up (10-12 days after dosing). | 
| Cmax,u of BAY2327949 | Cmax,u: Cmax based on the unbound plasma concentrations of the study drug | From pre-dose until follow-up (10-12 days after dosing). | 
| AUCu of BAY2327949 | AUC(0-tlast)u will be used as primary variables if mean AUC(tlast-∞) >20% of AUC | From pre-dose until follow-up (10-12 days after dosing). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency and nature of treatment-emergent adverse events |  | Approximate 14 days (from starting treatment to end of follow-up) | 
| Urinary volume |  | From Day -1 until Day 4 (72h after dosing) | 
| Fluid balance |  | From Day -1 until Day 4 (72h after dosing) |